Corvus Pharma To Present Preclinical Data Highlighting Potential Of Soquelitinib To Treat Systemic Sclerosis At EULAR 2025 Congress

Author: Benzinga Newsdesk | June 11, 2025 06:19am

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14, 2025 in Barcelona. The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal. It was selected as a top 10 abstract by the Emerging EULAR Network (EMEUNET), a network of young rheumatologists and researchers in the field of rheumatology in Europe and beyond.

Posted In: CRVS